Athersys (ATHX) Set to Announce Quarterly Earnings on Tuesday

Athersys (NASDAQ:ATHX) is set to post its quarterly earnings results after the market closes on Tuesday, November 6th. Analysts expect Athersys to post earnings of ($0.08) per share for the quarter.

Athersys (NASDAQ:ATHX) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported $0.05 EPS for the quarter. The business had revenue of $19.39 million for the quarter, compared to analysts’ expectations of $12.82 million. Athersys had a negative return on equity of 61.52% and a negative net margin of 106.99%. On average, analysts expect Athersys to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NASDAQ:ATHX opened at $2.02 on Monday. The stock has a market cap of $279.94 million, a price-to-earnings ratio of -6.97 and a beta of -0.35. Athersys has a 52 week low of $1.29 and a 52 week high of $3.09.

In other news, insider William Lehmann, Jr. sold 15,000 shares of Athersys stock in a transaction dated Tuesday, September 18th. The stock was sold at an average price of $1.88, for a total value of $28,200.00. Following the sale, the insider now directly owns 517,373 shares of the company’s stock, valued at $972,661.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laura K. Campbell sold 28,868 shares of Athersys stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $2.01, for a total value of $58,024.68. Following the completion of the sale, the insider now directly owns 590,424 shares in the company, valued at $1,186,752.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,668 shares of company stock worth $120,503. Insiders own 18.60% of the company’s stock.

A number of equities research analysts have commented on the company. BidaskClub cut Athersys from a “hold” rating to a “sell” rating in a report on Friday, October 26th. Zacks Investment Research cut Athersys from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, Maxim Group reissued a “buy” rating and set a $6.00 price target on shares of Athersys in a report on Tuesday, July 31st.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Further Reading: Hedge Funds – Risk or Reward?

Earnings History for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply